- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04742777
Efecto de la inhibición de mTOR y otras intervenciones de modulación del metabolismo en los ancianos [Subestudio Rapa y cMRI para evaluar la función cardíaca] (mTOR)
Efecto de la inhibición de mTOR y otras intervenciones moduladoras del metabolismo en los ancianos: consecuencias inmunitarias, cognitivas y funcionales ((Subestudio E - RAPA cMRI con LGE)
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).
Substudy E will evaluate the Rapamycin and Cardiac Function.
Descripción general del estudio
Descripción detallada
The main study has completed and results are reported (NCT02874924)
Purpose of Sub-study E - Rapamycin and cMRI to evaluate cardiac function:
The over-arching hypothesis is that RAPA treatment will effect simultaneous improvement in parameters known to be negatively impacted by aging. For example, systemic inflammation is higher in older individuals and contributes to the development of age-related pathologies affecting both the heart and the vasculature. In particular, evidence indicates that aging-associated alterations in inflammatory and pro-fibrotic pathways are critically involved in the etiology of age-related declines. The study team hypothesize that mTOR antagonism with RAPA will improve detrimental age-related pathologies affecting the heart in elderly humans.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- The University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Estados Unidos, 78229
- Audie L. Murphy Memorial Veterans Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- men and women 70-95 years of age.
- Subjects will be in good general health with all chronic diseases (hypertension, coronary artery disease, etc.) clinically stable. Selected subjects will be in good health (Per the World Health Organization good health will be defined as complete physical, mental, and social well-being and not merely the absence of disease or infirmity.
- For our purposes all diseases or infirmities will be clinically stable whether managed by medications or not.
- All ethnicities will be included.
- For cardiac and brain imaging by MRI, a pre-MRI screening questionnaire will be used to assess MRI safety and neurological health.
Exclusion Criteria:
- Diabetes, (with A1c ≥6.5 or if treated with medication affecting glucose homeostasis History of skin ulcers or poor wound healing,
- Smoking,
- Liver disease,
- Anti-coagulation,
- Treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin, etc) due to its role in RAPA metabolism,
- Treatment (>30days of therapy or long term) with a systemic immunosuppressant (prednisone, etc.) within the last year,
- History of recent (within 6 months) Myocardial Infarction or active Coronary Disease,
- Patients with history of recent (within 6 months) intestinal disorders,
- Exclusion criteria for MRI scan: known claustrophobia, metal implants in soft tissue of the body including pacemakers, aneurysm clips, ferrous metal fragments not anchored to bone (bullets, BBs, shrapnel, metal shavings), implanted medication pumps, and oral-facial metal appliances that are permanently secured but may result in low image quality. Participants may also be excluded for history of severe head trauma, brain injury, brain surgery, inflammation of the brain, or history of seizures.
- Positive COVID19 test.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Rapamycin
Rapamycin 1mg for 8 weeks |
Taken orally 1mg daily for 8 weeks
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Systolic Function
Periodo de tiempo: Baseline to 8 weeks
|
Test whether RAPA improves systolic function in elderly subjects. Cardiac MRI will be measured before and after 8 weeks of RAPA administration using 3T MRI. From collected MRI data, the study team will quantify change in systolic volumes. |
Baseline to 8 weeks
|
|
Diastolic Function
Periodo de tiempo: Baseline to 8 weeks
|
Test whether RAPA improves diastolic function in elderly subjects.Cardiac MRI will be measured before and after 8 weeks of RAPA administration using 3T MRI. From collected MRI data, the study team will quantify change in diastolic volumes. |
Baseline to 8 weeks
|
|
Aortic Cross-Sectional Area
Periodo de tiempo: Baseline to 8 weeks
|
Test whether RAPA increases aortic compliance in elderly subjects. Aortic MRI will be measured before and after 8 weeks of RAPA using 3T MRI. The study team will quantify distal descending aortic cross-sectional area to assess aortic function/compliance effects. |
Baseline to 8 weeks
|
|
Aortic Distensibility
Periodo de tiempo: Baseline to 8 weeks
|
Test whether RAPA increases aortic compliance in elderly subjects. Aortic MRI will be measured before and after 8 weeks of RAPA using 3T MRI. The study team will quantify change in distal descending aortic distensibility to assess aortic function/compliance effects. |
Baseline to 8 weeks
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Dean L Kellogg, Jr., MD PhD, The University of Texas Health Science Center at San Antonio
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HSC20120304H (Addendum)
- 5P30AG044271-07 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All IPD that underlie results in a publication will be shared.
Marco de tiempo para compartir IPD
Data will become available at study completion at the time of journal publication.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .